bv-6

BV6 is an antagonist of c-IAP1 and XIAP, members of the inhibitors of apoptosis (IAP) family.

BV600022 is an osteoadsorptive bisphosphonate-ciprofloxacin conjugate with antibacterial activity.

(±)19(20)-EDP ethanolamide is an ω-3 endocannabinoid epoxide and cannabinoid (CB) receptor agonist (EC50s = 108 and 280 nM for CB1 and CB2, respectively). It is produced through direct epoxygenation of docosahexaenoyl ethanolamide by cytochrome P450 (CYP) epoxygenases. (±)19(20)-EDP ethanolamide (25 μM) reduces the viability of 143B metastatic osteosarcoma cells. It decreases the production of IL-6 and increases the production of IL-10 when used at concentrations ranging from 2.5 to 10 μM in BV-2 microglia stimulated by LPS and decreases LPS-induced cytotoxicity when used at concentrations ranging from 5 to 10 μM. It also decreases nitrite production when used at a concentration of 7.5 μM, an effect that can be partially reversed by the CB2 receptor antagonist AM630 and the PPARγ antagonist GW 9662 . (±)19(20)-EDP ethanolamide induces vasodilation of isolated preconstricted bovine coronary arteries (ED50 = 1.9 μM) and reduces tube formation by human microvascular endothelial cells (HMVECs) in a Matrigel assay.

PapRIV, a quorum-sensing heptapeptide derived from B. cereus, undergoes synthesis as a 48-amino acid polypeptide. This compound is secreted and then extracellularly processed by NprB proteases into its active form. At concentrations ranging from 1-25 µM, PapRIV triggers the production of IL-6 and TNF-α, as well as NF-κB translocation, specifically in BV-2 microglia cells.

NCI 126224 is a Toll-like receptor 4 (TLR4) antagonist that selectively inhibits nitric oxide production induced by the TLR4 agonist LPS in RAW 264.7 macrophages (IC50 = 0.31 µM), while exhibiting weaker effects against the TLR7/8 agonist R-848, TLR1/2 agonist Pam3CSK4, and TLR3 agonist poly(I:C). NCI 126224 also inhibits FSL-1-induced NO production at 0.6 µM and suppresses LPS-induced NF-κB activity in BV-2 glial cells, while reducing IL-1β and TNF-α levels in RAW 264.7 cells (IC50s of 5.92 and 1.54 µM, respectively). 0.42, and 1.54 µM, respectively), demonstrating its significant value in studies of inflammatory and innate immune signaling pathways.

(±)17(18)-EpETE-Ethanolamide, an ω-3 endocannabinoid epoxide, originates from eicosapentaenoic ethanolamide (EPEA) through cytochrome P450 (CYP) epoxygenases action and is decomposed by soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FA, AH). Its endogenous synthesis occurs in LPS-stimulated and EPEA-supplemented BV-2 microglia cells, a process inhibited by the CYP inhibitor ketoconazole. This compound mitigates IL-6 and nitrite levels while enhancing IL-10 production following LPS exposure in BV-2 microglia. At a dose of 50 µM, it prevents platelet aggregation caused by arachidonic acid but not that triggered by ADP, collagen, or ristocetin. Additionally, it facilitates the dilation of constricted bovine coronary arteries (ED50= 1.1 µM) and blocks VEGF-driven tubulogenesis in human microvascular endothelial cells (HMVECs).

Theleganbanin D is a derivative of p-terphenyl discovered in the fungus dry 'Thelephora ganbajun'. Theleganbanin D inhibits the production of TNF-α, IL-6, and IL-1β in LPS-induced BV-2 microglial cells and shows potential for research in neurodegenerative diseases.

Theleganbanin B is a p-terphenyl derivative discovered in the mushroom (Thelephora ganbajun). It inhibits the production of TNF-α, IL-6, and IL-1β in BV-2 microglial cells induced by LPS. Theleganbanin B also suppresses the phosphorylation of JAK2/STAT3 and holds potential for neurodegenerative disease research.

2-O-Methylatromentin is an anti-neuritogenic agent that inhibits the production of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in BV-2 microglial cells induced by Lipopolysaccharides [LPS]. 2-O-Methylatromentin is applicable for research in neuroinflammation-related diseases.

PapRIV is an agonist of BV-2 microglial cells that activates these cells via an NF-κB-dependent pathway. It induces the expression of pro-inflammatory cytokines such as IL-6 and TNFα and enhances the production of reactive oxygen species (ROS). Additionally, PapRIV is capable of crossing the blood-brain barrier.